Allocation concealment  and blinding: when  ignorance is bliss

Peta M Forder,* Val J Gebski,^† Anthony C Keech^‡

NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450.

Correspondence: enquiry@ctc.usyd.edu.au

1. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 2002; 136: 254-259.
2. Beller EM, Gebski V, Keech AC. Randomisation in clinical trials. Med J Aust 2002; 177: 565-567. <MJA full text>
3. Forder PM, Gebski VJ, Keech AC. Allocation concealment and blinding: when ignorance is bliss. Med J Aust 2005; 182: 87-89. <MJA full text>
4. Karlowski TR, Chalmers TC, Frenkel LD, et al. Ascorbic acid for the common cold. JAMA 1975; 231: 1038-1042.
5. Chalmers TC. Discussion. To the preceding article by H Hemilä. J Clin Epidemiol 1996; 49: 1085.
6. Hemilä H. Discussion. To the dissent by Thomas Chalmers. J Clin Epidemiol 1996; 49: 1087.
7. Altman DG, Schulz KF, Moher D, et al for the CONSORT Group. The revised CONSORT statement for reporting randomised trials : explanation and elaboration. Ann Intern Med 2001; 134: 663-694.
8. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002; 359: 614–618.

Online responses are no longer available. Please refer to our instructions for authors page for more information.